Tekla Life Sciences Investors vs ANNSD
A head-to-head of Tekla Life Sciences Investors (HQL) and ANNSD (ANNSD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | HQL | ANNSD |
|---|---|---|
| Market Cap | $553.12M | $457.05B |
| P/E (TTM) | 3.35 | 12.29 |
| Forward P/E | 0.00 | 16.69 |
| P/S | 285.35 | 42.74 |
| P/B | 1.12 | 4.36 |
| EV/EBITDA | 0.00 | 10.72 |
| Dividend Yield | 10.14% | 3.20% |
| Profit Margin | 505.41% | 34.92% |
| Gross Margin | 100.00% | 73.91% |
| Operating Margin | 99.08% | 47.03% |
| Revenue Growth (YoY) | +463.30% | +102.66% |
| FCF Yield | — | 0.27% |
| Debt / Equity | — | 52.51 |
| Current Ratio | 1.74 | 1.88 |
Which is better: Tekla Life Sciences Investors or ANNSD?
- ✓Larger by market cap: ANNSD
- ✓Cheaper valuation (lower P/E): Tekla Life Sciences Investors
- ✓Higher dividend yield: Tekla Life Sciences Investors
- ✓More profitable (net margin): Tekla Life Sciences Investors
- ✓Faster revenue growth: Tekla Life Sciences Investors
Across 9 available metrics, Tekla Life Sciences Investors leads 7–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Tekla Life Sciences Investors with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.